JonesResearch analyst Soumit Roy downgraded CervoMed (CRVO) to Hold from Buy without a price target after the company’s Phase 2b trial in dementia with Lewy bodies did not meet the primary and secondary endpoints. Neflamapimod did not demonstrate statistically significant effects compared to placebo on primary and secondary endpoints at 16 weeks, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CRVO:
Questions or Comments about the article? Write to editor@tipranks.com